

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and
Waiver under 18 U.S.C. §208(b)(3)**

Marvin Meyer, Ph.D.

Committees: Endocrinologic & Metabolic Drugs
Advisory Committee and the
Advisory Committee for
Pharmaceutical Science Meeting

Meeting Date: October 4, 2006

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to the joint committees' discussions of FDA's efforts to assess the product quality of currently marketed levodopa sodium drug products. Earlier this year, FDA requested that manufacturers of currently marketed levodopa sodium products provide to it certain product release and stability information. The joint committee will consider FDA's analyses and any clinical significance. I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Unrelated Consulting	Affected Firm	Between \$10,001 and \$50,000 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

_____/S/_____
Signature of SGE

_____/8/23/06_____
Date